Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain.

Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M.

J Biol Chem. 2002 Jul 5;277(27):24818-25. Epub 2002 May 1.

2.

Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR.

Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML.

J Biol Chem. 1996 Feb 9;271(6):3154-62.

3.

VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding.

Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M.

J Cell Biochem. 2002;85(2):357-68.

PMID:
11948691
4.

Neuropilin-1 is a placenta growth factor-2 receptor.

Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, Baumann H, Neufeld G.

J Biol Chem. 1998 Aug 28;273(35):22272-8.

5.
6.

Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.

Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G.

J Biol Chem. 1995 Jun 23;270(25):15059-65.

7.

Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells.

Gitay-Goren H, Cohen T, Tessler S, Soker S, Gengrinovitch S, Rockwell P, Klagsbrun M, Levi BZ, Neufeld G.

J Biol Chem. 1996 Mar 8;271(10):5519-23.

9.

Characterization of a soluble vascular endothelial growth factor receptor-immunoglobulin chimera.

Kaplan JB, Sridharan L, Zaccardi JA, Dougher-Vermazen M, Terman BI.

Growth Factors. 1997;14(4):243-56.

PMID:
9386989
10.
11.

Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected].

Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G.

J Biol Chem. 2000 Jun 16;275(24):18040-5. Erratum in: J Biol Chem 2000 Sep 22;275(38):29922.

12.

Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity.

Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, Klagsbrun M.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2573-8.

13.

Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors.

Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, Lemischka IR, Neufeld G.

J Biol Chem. 1994 Apr 29;269(17):12456-61.

14.

The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1.

Fuh G, Garcia KC, de Vos AM.

J Biol Chem. 2000 Sep 1;275(35):26690-5.

15.
16.

Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.

Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marmé D, Martiny-Baron G.

J Biol Chem. 1997 Apr 18;272(16):10382-8.

17.

Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling.

Beck H, Acker T, Püschel AW, Fujisawa H, Carmeliet P, Plate KH.

J Neuropathol Exp Neurol. 2002 Apr;61(4):339-50.

PMID:
11939589
18.

Solution structure of the heparin-binding domain of vascular endothelial growth factor.

Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA.

Structure. 1998 May 15;6(5):637-48.

19.

Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors.

Soker S, Goldstaub D, Svahn CM, Vlodavsky I, Levi BZ, Neufeld G.

Biochem Biophys Res Commun. 1994 Sep 15;203(2):1339-47.

PMID:
7522446
20.

Supplemental Content

Support Center